The company posted a 23% year-on-year decline in consolidated net profit at ₹119 crore for the March quarter, compared with ₹154 crore in the corresponding period last year.
Revenue from operations, however, rose 18.8% YoY to ₹2,290 crore from ₹1,928 crore, supported by healthy growth across business segments.
EBITDA declined marginally by 1.6% to ₹339.3 crore from ₹345 crore a year ago, while EBITDA margin contracted sharply to 14.8% from 17.9%, reflecting higher operating costs and pressure on profitability.
Following the earnings announcement, shares of Jubilant Pharmova fell to an intraday low of ₹988 on the NSE before recovering most of the losses to trade nearly flat at ₹1,008.
The board of directors recommended a final dividend of ₹5 per equity share of face value Re 1 each for FY26, translating into a 500% payout. The company has fixed July 24, 2026 as the record date for determining shareholder eligibility for the dividend payment. Subject to shareholder approval at the annual general meeting, the dividend will be paid within 30 days of the AGM.
Also Read: Info Edge Q4 Results: Stock jumps on margin expansion, market share gains
Despite the softer earnings performance, the sharp rise in revenue indicates continued demand momentum across the company’s pharmaceutical and healthcare businesses.
Jubilant Pharmova operates across pharmaceuticals, contract research and development, radiopharma, allergy therapy and drug discovery solutions, with a presence in both domestic and international markets.
